Trends in the Prevalence of Drug-Induced Parkinsonism in Korea
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Discontinuation of offending drugs can prevent drug-induced parkinsonism (DIP) before it occurs and reverse or cure itafterwards. The aim of this study was to investigate the prevalence of DIP and the utilization of offending drugs through an analysisof representative nationwide claims data. Materials and Methods: We selected DIP patients of ages ranging from 40 to 100 years old with the G21.1 code from the Korean NationalService Health Insurance Claims database from 2009 to 2015. The annual standardized prevalence of DIP was explored from2009 to 2015. Trends were estimated using the compound annual growth rate (CAGR) and the Cochran-Armitage test for DIP overthe course of 6 years. Additionally, the utilization of offending drugs was analyzed. Results: The annual prevalence of DIP was 4.09 per 100000 people in 2009 and 7.02 in 2015 (CAGR: 9.42%, p<0.001). Levosulpirideuse before and after DIP diagnosis showed a clear trend for decreasing utilization (CAGR: -5.4%, -4.3% respectively), whereas theCAGR for itopride and metoclopramide increased by 12.7% and 6.4%, respectively. In 2015, approximately 46.6% (858/1840 persons)of DIP patients were prescribed offending drugs after DIP diagnosis. The most commonly prescribed causative drug afterDIP diagnosis was levosulpiride. Conclusion: The prevalence of DIP has increased. To prevent or decrease DIP, we suggest that physicians reduce prescriptions ofbenzamide derivatives that have been most commonly used, and that attempts be made to find other alternative drugs. Additionally,the need for continuing education about offending drugs should be emphasized.
Abstract
Purpose: Discontinuation of offending drugs can prevent drug-induced parkinsonism (DIP) before it occurs and reverse or cure itafterwards. The aim of this study was to investigate the prevalence of DIP and the utilization of offending drugs through an analysisof representative nationwide claims data. Materials and Methods: We selected DIP patients of ages ranging from 40 to 100 years old with the G21.1 code from the Korean NationalService Health Insurance Claims database from 2009 to 2015. The annual standardized prevalence of DIP was explored from2009 to 2015. Trends were estimated using the compound annual growth rate (CAGR) and the Cochran-Armitage test for DIP overthe course of 6 years. Additionally, the utilization of offending drugs was analyzed. Results: The annual prevalence of DIP was 4.09 per 100000 people in 2009 and 7.02 in 2015 (CAGR: 9.42%, p<0.001). Levosulpirideuse before and after DIP diagnosis showed a clear trend for decreasing utilization (CAGR: -5.4%, -4.3% respectively), whereas theCAGR for itopride and metoclopramide increased by 12.7% and 6.4%, respectively. In 2015, approximately 46.6% (858/1840 persons)of DIP patients were prescribed offending drugs after DIP diagnosis. The most commonly prescribed causative drug afterDIP diagnosis was levosulpiride. Conclusion: The prevalence of DIP has increased. To prevent or decrease DIP, we suggest that physicians reduce prescriptions ofbenzamide derivatives that have been most commonly used, and that attempts be made to find other alternative drugs. Additionally,the need for continuing education about offending drugs should be emphasized.
참고문헌 (26)
- Brigo F, "Differentiating drug-induced parkinsonism from Parkinson’s disease : an update on non-motor symptoms and investigations", Parkinsonism Relat Disord, 20, pp.808~814 (2014)
- Klawans HL Jr, "Prolonged drug-induced Parkinsonism", Confin Neurol, 35, pp.368~377 (1973)
- Wenning GK, "Prevalence of movement disorders in men and women aged 50-89years(Bruneck Study cohort) : a population-based study", Lancet Neurol, 4, pp.815~820 (2005)
- Benito-León J, "Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain", Mov Disord, 18, pp.267~274 (2003)
- Foubert-Samier A, "Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort", Neurology, 79, pp.1615~1621 (2012)
- Noyes K, "What is the risk of developing parkinsonism following neuroleptic use", Neurology, 66, pp.941~943 (2006)
- 신혜원, "Drug-Induced Parkinsonism", Journal of Clinical Neurology, 8(1), pp.15~21 (2012), 대한신경과학회
- Ma HI, "Diabetes mellitus and drug-induced Parkinsonism : a case-control study", J Neurol Sci, 284, pp.140~143 (2009)
- López-Sendón JL, "Drug-induced parkinsonusm in the elderly : incidence, management and prevention", Drugs Aging, 29, pp.105~118 (2012)
- "Drugs@FDA 2017: FDA approved drug products" (2017)[URL]
- "Agency (MHRA) MaHpR" (2017)[URL]
- "Korea Health Insurance Review and Assessment Service Database 2014" (2015)[URL]
- Bondon-Guitton E, "Drug-induced parkinsonism : a review of 17 years'experience in a regional pharmacovigilance center in France", Mov Disord, 26, pp.2226~2231 (2011)
- Erro R, "Parkinsonism following neuroleptic exposure: a double-hit hypothesis?", Mov Disord, 30, pp.780~785 (2015)
- Belatti DA, "Declines in lower extremity amputation in the US Medicare population, 2000-2010", Foot Ankle Int, 34, pp.923~931 (2013)
- Armitage P, "Tests for linear trends in proportions and frequencies", Biometrics, 11, pp.375~386 (1955)
- Savica R, "Time trends in the incidence of Parkinson disease", JAMA Neurol, 73, pp.981~989 (2016)
- Barbosa MT, "Parkinsonism and Parkinson’s disease in the elderly : a community-based survey in Brazil(the Bambui study)", Mov Disord, 21, pp.800~808 (2006)
- Kim JS, "Combined use of(1)(2)(3)I-metaiodobenzylguanidine(MIBG)scintigraphy and dopamine transporter(DAT)positron emission tomography(PET)predicts prognosis in drug-induced Parkinsonism(DIP) : a 2-year follow-up study", Arch Gerontol Geriatr, 56, pp.124~128 (2013)
- 김중석, "Levosulpiride에 의해 유발된 파킨슨 증후군", 대한신경과학회지, 21(4), pp.15~421 (2003), 대한신경과학회
- Shin HW, "Levosulpiride-induced movement disorders", Mov Disord, 24, pp.2249~2253 (2009)
- 안현정, "Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics", Journal of Korean Medical Science, 30(9), pp.1328~1333 (2015), 대한의학회
- Kim YD, "Cognitive dysfunction in drug induced parkinsonism(DIP)", Arch Gerontol Geriatr, 53, pp.e222~6 (2011)
- Tonini M, "5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract", Dig Liver Dis, 35, pp.244~250 (2003)
- Eamonn M M Quigley, "Prokinetics in the Management of Functional Gastrointestinal Disorders", Journal of Neurogastroenterology and Motility (JNM), 21(3), pp.330~336 (2015), 대한소화기 기능성질환∙운동학회[DOI]
- Savica R, "Incidence and time trends of drug-induced parkinsonism : a 30-year population-based study", Mov Disord, 32, pp.227~234 (2017)